

KAROLINSKA INSTITUTET

CURRICULUM VITAE

1 NAME Gianluigi Savarese

2 BIRTH DATA August 19th, 1985

3 ADDRESS

Residence: Torsplan 8; 11365 Stockholm; Sweden

Workplace: Karolinska University Hospital; Norrbacka S1:02

4 PHONE AND EMAIL +46 76 416 5215 – gianluigi.savarese@ki.se

5 COURSES AND DEGREES

Medical degree (MD): October 21th, 2010 - University of Naples “Federico II”, Italy

Medical licence: 2010 - University of Naples “Federico II”, Italy

Board certified Cardiologist: June 30th, 2016 - University of Naples “Federico II”, Italy

UK full registration as cardiologist – GMC, 2016

Heart failure Specialist: October 27th, 2017 – University of Zurich, Switzerland

Swedish licence to practice medicine at specialist level (Cardiology) – September 2019

6 DOCTORAL DEGREE

PhD thesis Title: Karolinska Institutet, Department of Medicine, Cardiology Unit – Title: “Biomarkers for eligibility and surrogate endpoints in heart failure trials”. March 16th, 2018.

7 CURRENT POSITION

Associate Professor of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Consultant: Department of Cardiology; Tema Hjärta Kärl och Neuro; Karolinska Universitetssjukhuset; Stockholm; Sweden

8 PRIOR POSITIONS

May 2019 – February 2020; Senior Researcher (Forskare), Department of Medicine, Karolinska Institutet, Stockholm, Sweden

April 2018 – April 2019; Assistant Professor (Forskarassistent), Department of Medicine, Karolinska Institutet, Stockholm, Sweden

June 2015 – March 2018; PhD student, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

July 2011 – June 2016; Cardiologist in training, Federico II University Hospital, Naples, Italy

June 2013 – December 2014; Research assistant, University of Zurich, Center for Molecular Cardiology.

9 SELECTED ACADEMIC DISTINCTIONS AND OTHER MERITS

- Board of the Heart failure Association of the European Society of Cardiology (2020 – ongoing)
- Member of the European Society of Cardiology – Heart Failure Association committee for the Atlas of Heart failure (2019 – ongoing)
- Member of the committee on Surveys, Registry and Epidemiology Committee of the Heart Failure Association – European Society of Cardiology (2016 – 2020)
- Board Member, Committee on Education and Digital Health, Heart Failure Association, European Society of Cardiology (2020 – ongoing)
- Board Member, Committee on Diabetes and Hypertension, Heart Failure Association, European Society of Cardiology (2020 – ongoing)
- Secretary of the European Society of Cardiology – Working Group on Cardiovascular Pharmacotherapy (2018 – 2020)
- Board member of the European Society of Cardiology - Working Group on Cardiovascular Pharmacotherapy (2016 – ongoing)
- Chairman of the European Society of Cardiology – Cardiovascular Pharmacotherapists and Trialists of Tomorrow (2016 – ongoing)
- Steering committee member for the EMPERIAL trials
- Advanced Fellowship in Cardiovascular Trials – Global Cardiovascular clinical trialists (CVCT) forum-Boehringer Ingelheim (2018 – ongoing)
- Scholar of the Italian Society of Cardiology (2018 - ongoing)

- Young Investigator Award from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)(finalist) (HFA Congress 2018, Vienna, Austria)
- Young Investigator Award on Population Science from European Society of Cardiology (finalist) (ESC Congress 2017, Barcelona, Spain)
- Fellow of the Heart Failure Association (FHFA)(2015 – ongoing)
- Fellow of the European Society of Cardiology (FESC)(2014 – ongoing)
- Young investigator award from the Italian Society of Cardiology (2013)
- Best Poster Award European Society of Cardiology Congress (ESC Congress 2012, Munich Germany).
- Member of the Italian Society of Cardiology (2010 – ongoing)

10 LANGUAGE SKILLS

Italian – mother tongue

English – C1

Swedish – C1

German – A2

SCIENTIFIC ACTIVITIES

1 CURRENT SCIENTIFIC ACTIVITY

Research area: Heart Failure; Cardiovascular Diseases; Epidemiology; Pharmacotherapy

2 SCIENTIFIC PUBLICATIONS

2.1 Bibliometric parameters from Web of Science

Tag field generated from MeSH terms by Karolinska Bibliometrics:



OVERALL 159 PUBLICATIONS

- 87 original works
- 2 book chapters
- 70 reviews/editorials

2.2 List of all original works

1. Khan Minhas AM, Salah HM, Khan MS, Rao VN, Tedford RJ, ReddyMD YNV, Caughey MC, **Savarese G**, Greene SJ, Michos ED, Fudim M.
Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States between 2005-2018.
Am J Med Sci. 2022. doi: 10.1016/j.amjms.2022.01.009. PMID: 35090870
2. Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drożdż J, Seferovic P, Rosano GMC, Piepoli M, Mebazaa A, McDonagh T, Lainscak M, **Savarese G**, Ferrari R, Maggioni AP, Lund LH; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators.

A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.

Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ehf.2408. PMID: 34962044

3. Kapelios CJ, Lund LH, Benson L, Dahlström U, Rosano GMC, Hauptman PJ, Savarese G.
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry.
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab079. PMID: 34921603
4. Lund LH, Savarese G, Venkateshvaran A, Benson L, Lundberg A, Donal E, Daubert JC, Oger E, Linde C, Hage C.
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
ESC Heart Fail. 2022;9:164-177. doi: 10.1002/ehf2.13705. PMID: 34811954
5. Fudim M, Devaraj S, Chukwurah M, Ajam T, Razaghizad A, Salah HM, Sharma A, Savarese G, Vaduganathan M, Kamalesh M.
Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis.
Int J Cardiol. 2022;346:30-34. doi: 10.1016/j.ijcard.2021.11.032. PMID: 34800593
6. Lim YMF, Molnar M, Vaartjes I, Savarese G, Eijkemans MJC, Uijl A, Vradi E, Suzart-Woischnik K, Brugts JJ, Brunner-La Rocca HP, Blanc-Guillemaud V, Couvelard F, Baudier C, Dyszynski T, Waechter S, Lund LH, Hoes AW, Tyl B, Asselbergs FW, Gerlinger C, Grobbee DE, Cronin M, Koudstaal S
Generalisability of Randomised Controlled Trials in Heart Failure with Reduced Ejection Fraction.
Eur Heart J Qual Care Clin Outcomes. 2021. doi: 10.1093/ehjqcco/qcab070. PMID: 34596659
7. Kapelios CJ, Canepa M, Benson L, Hage C, Thorvaldsen T, Dahlström U, Savarese G, Lund LH.
Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry.
Int J Cardiol. 2021:S0167-5273(21)01334-6. PMID: 34517016
<https://pubmed.ncbi.nlm.nih.gov/34517016/>
8. Schrage B, Lund LH, Melin M, Benson L, Uijl A, Dahlström U, Braunschweig F, Linde C, Savarese G.
Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
Europace. 2021. doi: 10.1093/europace/euab233. PMID: 34486653
<https://pubmed.ncbi.nlm.nih.gov/34486653/>

9. Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, **Savarese G.**
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2338. PMID: 34476878
<https://pubmed.ncbi.nlm.nih.gov/34476878/>
10. Shahim A, Hourqueig M, Donal E, Oger E, Venkateshvaran A, Daubert JC, **Savarese G**, Linde C, Lund LH, Hage C.
Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study.
ESC Heart Fail. 2021. doi: 10.1002/ehf2.13533. PMID: 34374216
<https://pubmed.ncbi.nlm.nih.gov/34374216/>
11. **Savarese G**, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, Inzucchi SE, Koudstaal S, Ofstad AP, Schrage B, Vedin O, Wanner C, Zannad F, Zwiener I, Butler J.
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial
J Card Fail. 2021;27:888-895. PMID: 34364665
<https://pubmed.ncbi.nlm.nih.gov/34364665/>
12. Trevisan M, Fu EL, Xu Y, **Savarese G**, Dekker FW, Lund LH, Clase CM, Sjölander A, Carrero JJ.
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2287. PMID: 34196082
<https://pubmed.ncbi.nlm.nih.gov/34196082/>
13. Schrage B, Beer BN, Savarese G, Dabboura S, Yan I, Sundermeyer J, Becher PM, Grahn H, Seiffert M, Bernhardt A, Thiele H, Møller JE, Kluge S, Reichenspurner H, Kirchhof P, Blankenberg S, Westermann D.
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2274. PMID: 34145680
<https://pubmed.ncbi.nlm.nih.gov/34145680/>
14. **Savarese G**, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats AJS
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Eur J Heart Fail. 2021;23:1499-1511. doi: PMID: 34132001
<https://pubmed.ncbi.nlm.nih.gov/34132001/>
15. Meyer M, Du Fay Lavallaz J, Benson L, **Savarese G**, Dahlström U, Lund LH.
Association Between β -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry
J Card Fail. 2021;S1071-9164(21)00158-5. PMID: 33971289
<https://pubmed.ncbi.nlm.nih.gov/33971289/>

16. Uijl A, **Savarese G**, Vaartjes I, Dahlström U, Brugts JJ, Linssen GCM, van Empel V, Brunner-La Rocca HP, Asselbergs FW, Lund LH, Hoes AW, Koudstaal S.
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
Eur J Heart Fail. 2021 Jun;23(6):973-982. PMID: 33779119
<https://pubmed.ncbi.nlm.nih.gov/33779119/>
17. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, **Savarese G**, Huculeci R, Kazakiewicz D, Coats AJ; Developed in collaboration with the National Heart Failure Societies of the ESC member countries.
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019
Eur J Heart Fail. 2021. doi: 10.1002/ehf.2143. PMID: 33634931
<https://pubmed.ncbi.nlm.nih.gov/33634931/>
18. Schrage B, Becher PM, Goßling A, **Savarese G**, Dabboura S, Yan I, Beer B, Söffker G, Seiffert M, Kluge S, Kirchhof P, Blankenberg S, Westermann D.
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock
ESC Heart Fail 2021. doi: 10.1002/ehf2.13202. PMID: 33605565
<https://pubmed.ncbi.nlm.nih.gov/33605565/>
19. Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztof Wranicz J, **Savarese G**, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD.
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
Eur Heart J. 2021;42:700-710. doi: 10.1093/eurheartj/ehaa943. PMID: 33351892
<https://pubmed.ncbi.nlm.nih.gov/33351892/>
20. Chen X, **Savarese G**, Cai Y, Ma L, Lundborg CS, Jiang W, Wen Z, Lu W, Marrone G.
Tai Chi and Qigong Practices for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Evid Based Complement Alternat Med. 2020 Dec 14;2020:2034625. doi: 10.1155/2020/2034625. PMID: 33381195
<https://pubmed.ncbi.nlm.nih.gov/33381195/>
21. **Savarese G**, Benson L, Sundström J, Lund LH.
Association between Renin-Angiotensin-Aldosterone system inhibitor use and COVID-19 Hospitalization and death: A 1,4 million patient Nation-Wide registry analysis
Eur J Heart Fail. 2020. doi: 10.1002/ehf.2060. PMID: 33222412
<https://pubmed.ncbi.nlm.nih.gov/33222412/>

22. Fu EL, Uijl A, Dekker FW, Lund LH, **Savarese G**, Carrero JJ.
Association Between β -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease
Circ Heart Fail 2020. doi: 10.1161/CIRCHEARTFAILURE.120.007180.
PMID: 33070637
<https://pubmed.ncbi.nlm.nih.gov/33070637/>
23. **Savarese G**, Hage C, Benson L, Schrage B, Thorvaldsen T, Lundberg A, Fudim M, Linde C, Dahlström U, Rosano GMC, Lund LH.
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
J Intern Med 2020. doi: 10.1111/joim.13165. PMID: 32776357
<https://pubmed.ncbi.nlm.nih.gov/32776357/>
24. Schrage B, Lund LH, Benson L, Stolfo D, Ohlsson A, Westerling R, Westermann D, Strömberg A, Dahlström U, Braunschweig F, Ferreira JP, **Savarese G**.
Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure
Heart 2020. doi: 10.1136/heartjnl-2020-317216. PMID: 32769169
<https://pubmed.ncbi.nlm.nih.gov/32769169/>
25. Uijl A, Lund LH, Vaartjes I, Brugts JJ, Linssen GC, Asselbergs FW, Hoes AW, Dahlström U, Koudstaal S, **Savarese G**.
A registry-based algorithm to predict ejection fraction in patients with heart failure.
ESC Heart Fail 2020;7(5):2388-97. doi: 10.1002/ehf2.12779.
PMID: 32548911
<https://pubmed.ncbi.nlm.nih.gov/32548911/>
26. **Savarese G**, Settergren C, Schrage B, Thorvaldsen T, Löfman I, Sartipy U, Mellbin L, Meyers A, Farsani SF, Brueckmann M, Brodovicz KG, Vedin O, Asselbergs FW, Dahlström U, Cosentino F, Lund LH.
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design
Int J Cardiol 2020;313:76-82. doi: 10.1016/j.ijcard.2020.04.068. PMID: 32360702
<https://pubmed.ncbi.nlm.nih.gov/32360702/>
27. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, **Savarese G**, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group.
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Eur J Heart Fail 2020. doi: 10.1002/ehf.1793. PMID: 32243669
<https://pubmed.ncbi.nlm.nih.gov/32243669/>

28. Stolfo D, Albani S, **Savarese G**, Barbati G, Ramani F, Gigli M, Biondi F, Dal Ferro M, Zecchin M, Merlo M, Sinagra G.
Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis.
Int J Cardiol 2020;307:75-81.PMID: 32067834
<https://www.ncbi.nlm.nih.gov/pubmed/32067834>
29. Cooper LB, Benson L, Mentz RJ, **Savarese G**, DeVore AD, Carrero JJ, Dahlström U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH.
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
Eur J Heart Fail 2020. doi: 10.1002/ehhf.1757. PMID: 32078214
<https://www.ncbi.nlm.nih.gov/pubmed/32078214>
30. Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW, Koudstaal S, Sinagra G, Dahlström U, Rosano G, **Savarese G**.
Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry.
Eur J Heart Fail 2020;22:103-112. PMID: 31478583
<https://www.ncbi.nlm.nih.gov/pubmed/31478583>
31. Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde C, Braunschweig F, **Savarese G**.
Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
Circulation. 2019;140:1530-1539. PMID: 31476893
<https://www.ncbi.nlm.nih.gov/pubmed/31476893>
32. Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G, Dahlström U, **Savarese G**.
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
JACC Heart Fail 2019;7:505-515. PMID: 31146874
<https://www.ncbi.nlm.nih.gov/pubmed/31146874>
33. Faxén UL, Lund LH, Orsini N, Strömberg A, Andersson DC, Linde C, Dahlström U, **Savarese G**.
N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Int J Cardiol. 2019;287:66-72. PMID: 31005415
<https://www.ncbi.nlm.nih.gov/pubmed/31005415>
34. **Savarese G**, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.

Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases.

Eur Heart J Cardiovasc Pharmacother. 2019 Aug 8. pii: pvz036. doi: 10.1093/ehjcvp/pvz036. PMID: 31392312

<https://www.ncbi.nlm.nih.gov/pubmed/31392312>

35. Löfström U, Hage C, Savarese G, Donal E, Daubert JC, Lund LH, Linde C. **Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.**

ESC Heart Fail. 2019;6:830-839. PMID: 31207140

<https://www.ncbi.nlm.nih.gov/pubmed/31207140>

36. Savarese G, Jonsson Å, Hallberg AC, Dahlström U, Edner M, Lund LH. **Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.**

Int J Cardiol. 2020;298:59-65. PMID: 31521440

<https://www.ncbi.nlm.nih.gov/pubmed/31521440>

37. Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolli L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators. **Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.**

Eur J Heart Fail. 2019;21:1383-1397. PMID: 31132222

<https://www.ncbi.nlm.nih.gov/pubmed/31132222>

38. Savarese G, Lund LH, Dahlström U, Strömberg A. **Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization.**

J Am Heart Assoc. 2019;8:e011737. PMID: 31094284

<https://www.ncbi.nlm.nih.gov/pubmed/31094284>

39. Chen X*, Savarese G*, Dahlström U, Lund LH, Fu M. **Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.**

Clin Res Cardiol. 2019;108:1394-1405. PMID: 30980205 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/30980205>

40. Savarese G*, Vedin O*, D'Amario D, Uijl A, Dahlstrom U, Rosano G, Lam CSP, Lund LH

Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure

JACC Heart Fail 2019;7:306-317. PMID: 30852236 *Equal contribution
<https://www.ncbi.nlm.nih.gov/pubmed/30852236>

41. **Savarese G**, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.
Empagliflozin Is Associated With a Lower Risk of Postacute Heart Failure Rehospitalization and Mortality. Insights From the EMPA-REG OUTCOME Trial
Circulation 2019;139:1458-1460. PMID: 30855996
<https://www.ncbi.nlm.nih.gov/pubmed/30855996>

42. **Savarese G**, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B, Lund LH, Carrero JJ.
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
JACC Heart Fail 2019;7:65-76. PMID: 30553905
<https://www.ncbi.nlm.nih.gov/pubmed/30553905>

43. Sartipy U, **Savarese G**, Dahlström U, Fu M, Lund LH.
Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.
Eur J Heart Fail 2019;21:471-479. PMID: 30698317
<https://www.ncbi.nlm.nih.gov/pubmed/30698317>

44. **Savarese G**, Dahlström U, Vasko P, Pitt B, Lund LH
Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study
Eur Heart J 2018;39:4257-4265. PMID: 30351407
<https://www.ncbi.nlm.nih.gov/pubmed/30351407>

45. Akhmedov A, Bonetti NR, Reiner MF, Spescha RD, Amstalden H, Merlini M, Gaul DS, Diaz-Cañestro C, Spescha RS, Semerano A, Giacalone G, **Savarese G**, Montecucco F, Kulic L, Nitsch RM, Matter CM, Kullak-Ublick GA, Sessa M, Lüscher TF, Beer JH, Liberale L, Camici GG.
Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury.
J Cereb Blood Flow Metab 2019;39:2233-2245. PMID: 30073881
<https://www.ncbi.nlm.nih.gov/pubmed/30073881>

46. **Savarese G**, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, Lund LH.
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
Eur J Heart Fail 2018;20:1326-1334. PMID: 29578280
<https://www.ncbi.nlm.nih.gov/pubmed/29578280>

47. **Savarese G**, Orsini N, Hage C, Dahlström U, Vedin O, Rosano GMC, Lund LH.

***Associations with and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure with Preserved vs. Mid-Range vs. Reduced Ejection Fraction.**

J Card Fail 2018;24:365-374. PMID: 29597053

<https://www.ncbi.nlm.nih.gov/pubmed/29597053>

48. Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH.

***Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.**

JACC Heart Fail 2018;6:246-256. PMID: 29428439

<https://www.ncbi.nlm.nih.gov/pubmed/29428439>

49. Savarese G, Sartipy U, Friberg L, Dahlström U, Lund LH.

Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.

Heart 2018;104:1093-1100. PMID: 29371374

<https://www.ncbi.nlm.nih.gov/pubmed/29371374>

50. Savarese G*, Gargiulo P*, D'Amore C, De Martino F, Lund LH, Marsico F, Dellegrottaglie S, Marciano C, Trimarco B, Perrone-Filardi P.

Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.

Nutr Metab Cardiovasc Dis 2017;27:1081-1088. PMID: 29113708 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/29113708>

51. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CSP, Lund LH.

A comprehensive population-based characterization of heart failure with mid-range ejection fraction.

Eur J Heart Fail 2017;19:1624-1634. PMID: 28948683

<https://www.ncbi.nlm.nih.gov/pubmed/28948683>

52. Das D*, Savarese G*, Dahlström U, Fu M, Howlett J, Ezekowitz JA, Lund LH.

Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.

Circ Heart Fail 2017;10. pii: e004112. PMID: 28903983 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/28903983>

53. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OÖ, Savarese G, Dahlström U, Lund LH.

Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.

Circ Heart Fail 2017;10. pii: e003875. PMID: 28615366

<https://www.ncbi.nlm.nih.gov/pubmed/28615366>

54. Reiner MF, Breitenstein A, Holy EW, Glanzmann M, Amstalden H, Stämpfli SF, Bonetti NR, Falk V, Keller S, **Savarese G**, Benussi S, Maisano F, Lüscher TF, Beer JH, Steffel J, Camici GG.
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
Eur Heart J 2017;38:916-919. PMID: 28065908
<https://www.ncbi.nlm.nih.gov/pubmed/28065908>
55. Reiner MF, Akhmedov A, Stivala S, Keller S, Gaul DS, Bonetti NR, **Savarese G**, Glanzmann M, Zhu C, Ruf W, Yang Z, Matter CM, Lüscher TF, Camici GG, Beer JH.
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Cardiovasc Res 2017;113:61-69. PMID: 28028070
<https://www.ncbi.nlm.nih.gov/pubmed/28028070>
56. **Savarese G**, Hage C, Orsini Nm Dahlstrom U, Perrone-Filardi P, Rosano MCG, Lund LH
***Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction**
Circ Heart Fail 2016;9. pii: e003105. PMID: 28029640
<https://www.ncbi.nlm.nih.gov/pubmed/28029640>
57. **Savarese G**, Donal E, Hage C, Oger E, Persson H, Daubert JC, Linde C, Lund LH; KaRen investigators
***Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.**
Int J Cardiol 2016;226:65-70. PMID: 27788392
<https://www.ncbi.nlm.nih.gov/pubmed/27788392>
58. Merlini M, Shi Y, Keller S, **Savarese G**, Akhmedov A, Derungs R, Spescha RD, Kulic L, Nitsch R, Lüscher T, Camici G.
Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease.
Am J Physiol Heart Circ Physiol 2017;312:H232-H238. PMID: 27836896
<https://www.ncbi.nlm.nih.gov/pubmed/27836896>
59. **Savarese G**, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Int J Cardiol 2016;220:595-601. PMID: 27390996
<https://www.ncbi.nlm.nih.gov/pubmed/27390996>
60. Rapacciuolo A, Perrone Filardi P, Cuomo R, Mauriello V, Quarto M, Kisslinger A, **Savarese G**, Illario M, Tramontano D.

The impact of social and cultural engagement and dieting on well-being and resilience in a group of residents in the metropolitan area of Naples.

J Aging Res 2016;2016:4768420. PMID: 27298737

<https://www.ncbi.nlm.nih.gov/pubmed/27298737>

61. Ricci F, Di Castelnuovo A, **Savarese G**, Perrone Filardi P, De Caterina R.
ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.

Int J Cardiol 2016;217:128-134. PMID: 27179902

<https://www.ncbi.nlm.nih.gov/pubmed/27179902>

62. **Savarese G**, Giugliano RP, Rosano GMC, McMurray J, Magnani G, Filippatos G, Dellegrottaglie S, Lund LH, Trimarco B, Perrone-Filardi P.
Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis

JACC Heart Fail 2016;4:870-880. PMID: 27614940

<https://www.ncbi.nlm.nih.gov/pubmed/27614940>

63. **Savarese G**, Savonitto S, Lund LH, Paolillo S, Marciano C, Dellegrottaglie S, Parente A, Trimarco B, Luscher TF, Perrone-Filardi P
Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients

Eur Heart J Cardiovasc Pharmacother 2016;2:218-28. PMID: 27533949

<https://www.ncbi.nlm.nih.gov/pubmed/27533949>

64. Giamundo A, Canciello G, Rapacciuolo A, Musella F, **Savarese G**, Strisciuglio T, Stabile E, Izzo R, Trimarco B, Losi MA.
Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy.

Int J Cardiol 2016;212:198-200. PMID: 27043060

<https://www.ncbi.nlm.nih.gov/pubmed/27043060>

65. **Savarese G**, Edner M, Dahlström U, Perrone-Filardi P, Hage C, Cosentino F, Lund LH.
Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.

Int J Cardiol 2015;199:415-423. PMID: 26247798

<https://www.ncbi.nlm.nih.gov/pubmed/26247798>

66. **Savarese G**, De Ferrari GM, Rosano GMC, Perrone-Filardi P.
Safety and efficacy of ezetimibe: a meta-analysis

Int J Cardiol 2015;201:247-52. PMID: 26301648

<https://www.ncbi.nlm.nih.gov/pubmed/26301648>

67. Paolillo S, Rengo G, Pellegrino T, Formisano R, Pagano G, Gargiulo P, **Savarese G**, Carotenuto R, Petraglia L, Rapacciuolo A, Perrino C, Piscitelli S, Attenua E, Del Guercio L, Leosco D, Trimarco B, Cuocolo A, Perrone-Filardi P.

Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure.

Eur Heart J Cardiovasc Imaging 2015;16:1148-53. PMID: 25845954

<https://www.ncbi.nlm.nih.gov/pubmed/25845954>

68. Spescha RD, Klohs J, Semerano A, Giacalone G, Derungs RS, Reiner MF, Rodriguez Gutierrez D, Mendez-Carmona N, Glanzmann M, **Savarese G**, Kränkel N, Akhmedov A, Keller S, Mocharla P, Kaufmann MR, Wenger RH, Vogel J, Kulic L, Nitsch RM, Beer JH, Peruzzotti-Jametti L, Sessa M, Lüscher TF, Camici GG.

Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.

Eur Heart J 2015;36:1590-1600. PMID: 25904764

<https://www.ncbi.nlm.nih.gov/pubmed/25904764>

69. Reiner MF, Martinod K, Stivala S, **Savarese G**, Camici GG, Lüscher TF, Wagner DD, Beer JH.

Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice.

Thromb Haemost 2015;113:177-84. PMID: 25231375

<https://www.ncbi.nlm.nih.gov/pubmed/25231375>

70. Perrone-Filardi P*, **Savarese G***, Scarano M, Cavazzina R, Trimarco B, Minneci S, Maggioni AP, Tavazzi L, Tognoni G, Marchioli R.

Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial.

Int J Cardiol 2014;178C:85-90. PMID: 25464226 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/25464226>

71. **Savarese G**, Rosano GMC, Parente A, D'Amore C, Reiner MF, Camici GG, Trimarco B, Perrone-Filardi P.

Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.

Int J Cardiol 2014;177:152-60. PMID: 25499365

<https://www.ncbi.nlm.nih.gov/pubmed/25499365>

72. **Savarese G**, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.

Int J Cardiol 2014;181C:239-244. PMID: 25528528

<https://www.ncbi.nlm.nih.gov/pubmed/25528528>

73. Shi Y*, **Savarese G***, Perrone-Filardi P, Lüscher TF, Camici GG.

Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc.

Int J Cardiol 2014;175:446-50. PMID: 25012499 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/25012499>

74. **Savarese G**, Musella F, D'Amore C, Vassallo E, Losco L, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P.
Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure
JACC Heart Fail 2014;2:148-58. PMID: 24720923
<https://www.ncbi.nlm.nih.gov/pubmed/24720923>
75. **Savarese G**, Dei Cas A, Rosano G, D'Amore C, Musella F, Mosca S, Reiner MF, Marchioli R, Trimarco B, Perrone-Filardi P.
Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials.
Int J Cardiol. 2014;172:403-10. PMID: 24502877
<https://www.ncbi.nlm.nih.gov/pubmed/24502877>
76. **Savarese G**, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P.
Benefits of statins in elderly subjects without established cardiovascular disease. A meta-analysis
J Am Coll Cardiol 2013;62:2090-9. PMID: 23954343
<https://www.ncbi.nlm.nih.gov/pubmed/23954343>
77. **Savarese G**, Rosano G, D'Amore C, Musella F, Della Ratta GL, Pellegrino AM, Formisano T, Vitagliano A, Cirillo A, Cice G, Fimiani L, Del Guercio L, Trimarco B, Perrone-Filardi P.
Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
Int J Cardiol 2013;169:262-70. PMID: 24063912
<https://www.ncbi.nlm.nih.gov/pubmed/24063912>
78. Gargiulo P, Dellegrottaglie S, Bruzzese D, **Savarese G**, Scala O, Ruggiero D, D'Amore C, Paolillo S, Agostoni Piergiuseppe, Bossone E, Soricelli A, Cuocolo A, Trimarco B, Perrone Filardi P.
The Prognostic Value of Normal Stress Cardiac Magnetic Resonance in Patients with Known or Suspected Coronary Artery Disease: A Meta-analysis
Circ Cardiovasc Imaging 2013;6:574-82. PMID: 23771988
<https://www.ncbi.nlm.nih.gov/pubmed/23771988>
79. Marsico M, Ruggiero D, Parente A, Pirozzi E, Musella F, Lo Iudice F, **Savarese G**, Losco T, Giugliano G, Rengo G, Dellegrottaglie S, Leosco D, Esposito G, Trimarco B, Perrone Filardi P.
Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with lower limbs arterial disease.
Atherosclerosis 2013;228:386-9. PMID: 23597978
<https://www.ncbi.nlm.nih.gov/pubmed/23597978>
80. **Savarese G**, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P.

Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.

PLoS ONE 2013;8:e58287. doi:10.1371/journal.pone.0058287. PMID: 23472172

<https://www.ncbi.nlm.nih.gov/pubmed/23472172>

81. **Savarese G**, Ferri C, Trimarco B, Rosano G, Dellegrottaglie S, Losco T, Casaretti L, D'Amore C, Gambardella F, Prastaro M, Rengo G, Leosco D, Perrone-Filardi P

Changes of serum uric acid levels and cardiovascular events. A meta-analysis.

Nutr Metab Cardiovasc Dis 2013;23:707-14. PMID: 23725772

<https://www.ncbi.nlm.nih.gov/pubmed/23725772>

82. Paolillo S, Rengo G, Pagano G, Pellegrino T, **Savarese G**, Femminella GD, Tuccillo M, Boemio A, Attena E, Formisano R, Petraglia L, Scopacasa F, Galasso G, Leosco D, Trimarco B, Cuocolo A, Perrone-Filardi P.

Impact of diabetes mellitus on cardiac sympathetic innervation in patients with heart failure. A iodine-123 meta-iodobenzylguanidine (I123MIBG) scintigraphic study.

Diabetes Care 2013;36:2395-401. PMID: 23530014

<https://www.ncbi.nlm.nih.gov/pubmed/23530014>

83. Rengo G, Pagano G, Squizzato A, Moja L, Femminella GD, de Lucia C, Komici K, Parisi V, **Savarese G**, Ferrara N, Perrone-Filardi P, Leosco D.

Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis.

PLoS One 2013;8:e52952. PMID: 23301006

<https://www.ncbi.nlm.nih.gov/pubmed/23301006>

84. **Savarese G**, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P,

A Meta-Analysis Reporting Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure.

J Am Coll Cardiol 2013;61:131-42. PMID: 23219304

<https://www.ncbi.nlm.nih.gov/pubmed/23219304>

85. **Savarese G**, Musella F, D'Amore C, Losco T, Marciano C, Gargiulo P, Rengo G, Dellegrottaglie S, Bossone E, Leosco D, Perrone-Filardi P

Hemodynamics, functional capacity and clinical events in pulmonary arterial hypertension.

Eur Respir J 2013;42:414-24. PMID: 23100502

<https://www.ncbi.nlm.nih.gov/pubmed/23100502>

86. Costanzo P*, **Savarese G***, Rosano G, Musella F, Casaretti L, Vassallo E, Paolillo S, Marsico F, Rengo G, Leosco D, Perrone-Filardi P.

Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients.

Int J Cardiol 2013;167:2757-64. PMID: 22795718 *Equal contribution

<https://www.ncbi.nlm.nih.gov/pubmed/22795718>

87. **Savarese G**, Musella F, Volpe M, MD, Paneni F, Perrone-Filardi P.
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Int J Cardiol 2013;167:2482-9. PMID: 22633671
<https://www.ncbi.nlm.nih.gov/pubmed/22633671>
88. Marciano C, Galderisi M, Gargiulo P, D'Amore C, Esposito R, Cuocolo A,
Savarese G, Casaretti L, Lo Iudice F, Esposito G, Rengo G, Leosco D, MD,
Perrone-Filardi P.
Effects of type 2 diabetes mellitus on microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. A perfusion scintigraphy and doppler transthoracic study.
Eur J Nucl Med Mol Imag 2012;39:1199-206. PMID: 22526959
<https://www.ncbi.nlm.nih.gov/pubmed/22526959>
89. Ruggiero D, **Savarese G**, Formisano R, Bologna A, Mattiello G, Pirozzi E,
Gambardella F, Lo Iudice F, Petraglia L, Vitagliano A, Casaretti L, Della Ratta
GL, Mosca S, Filardi PP.
Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries. A peripheral arterial tonometry study.
Monaldi Arch Chest Dis 2012;78:34-9. PMID: 22928402
<https://www.ncbi.nlm.nih.gov/pubmed/22928402>
90. Gargiulo P, Marciano C, **Savarese G**, D'Amore C, Paolillo S, Esposito G,
Santomauro M, Marsico F, Ruggiero D, Scala O, Marzano A, Cecere M,
Casaretti L, Perrone Filardi P.
Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries A digital reactive hyperemia study.
Int J Cardiol 2013;165:67-71. PMID: 21851998
<https://www.ncbi.nlm.nih.gov/pubmed/21851998>
91. **Savarese G**, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, Musella F,
Gargiulo P, Marciano C, Perrone-Filardi P.
Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials
J Am Coll Cardiol 2012;60:1192-201. PMID: 22995024
<https://www.ncbi.nlm.nih.gov/pubmed/22995024>
92. Prastaro M, Paolillo S, **Savarese G**, Dellegrottaglie S, Scala O, Ruggiero D,
Gargiulo P, Marciano C, Parente A, Cecere M, Musella F, Chianese D,
Scopacasa F, Perrone-Filardi P.
N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.
Eur J Echocardiogr 2011;12:506-513. PMID: 21685193
<https://www.ncbi.nlm.nih.gov/pubmed/21685193>
93. Gargiulo P, Petretta M, Bruzzese D, Cuocolo A, Prastaro M, D'Amore C,
Vassallo E, **Savarese G**, Marciano C, Paolillo S, Filardi PP.
Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis.
Eur J Nucl Med Mol Imaging 2011;38:2040-9. PMID: 21814850
<https://www.ncbi.nlm.nih.gov/pubmed/21814850>

2.5 List of general articles and book chapters

1. **Title Chapter: Definition, epidemiology and burden of disease – HFpEF.**

Authors: Lund LH and Savarese G

Book Title: The ESC Textbook of Cardiovascular Medicine – Third Edition

Editors: Luscher TF, Camm AJ, Serruys P, Maurer G

Publisher: Oxford Medicine

<https://oxfordmedicine.com/view/10.1093/med/9780198784906.001.0001/med-9780198784906-chapter-403>

2. **Title Chapter: Sex differences in heart failure**

Authors: Savarese G and D'Amario D

Book Title: Sex-specific analysis of cardiovascular function

Editors: Kerkhof P and Miller V

Publisher: Springer 2018

<https://www.springer.com/gp/book/9783319779317>

2.3 List of all other scientific works

1. Savarese G, Lund LH, Rosano GMC, Coats AJ.

New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021.

Eur Heart J Cardiovasc Pharmacother. 2021;7:e89-e90. doi:

10.1093/ehjcvp/pvab071. PMID: 34529057.

2. Rosano G, Jankowska EA, Ray R, Metra M, Abdelhamid M, Adamopoulos S, Anker SD, Bayes-Genis A, Belenkov Y, Gal TB, Böhm M, Chioncel O, Cohen-Solal A, Farmakis D, Filippatos G, González A, Gustafsson F, Hill L, Jaarsma T, Jouhra F, Lainscak M, Lambrinou E, Lopatin Y, Lund LH, Milicic D, Moura B, Mullens W, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Senni M, Thum T, Tocchetti CG, Van Linthout S, Volterrani M, Coats AJS.

COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2021 Nov;23(11):1806-1818. doi: 10.1002/ejhf.2356.PMID: 34612556

3. Rosano GMC, Allen LA, Abdin A, Lindenfeld J, O'Meara E, Lam CSP, Lancellotti P, Savarese G, Gottlieb SS, Teerlink J, Wintrich J, Böhm M

Drug Layering in Heart Failure: Phenotype-Guided Initiation.

JACC Heart Fail. 2021 Nov;9(11):775-783. doi: 10.1016/j.jchf.2021.06.011.

4. Uijl A, Lund LH, Asselbergs FW, Savarese G

Methodological issues in meta-analyses of real-world clinical data to infer causality.

Int J Cardiol. 2021;345:107-108. doi: 10.1016/j.ijcard.2021.10.029. PMID: 34688720

5. Lund LH, Hage C, **Savarese G**.
Implementation science and potential for screening in heart failure.
Eur Heart J. 2021. doi: 10.1093/eurheartj/ehab751. PMID: 34751776
6. Mullens W, Coats A, Seferovic P, Metra M, Mebazaa A, Ruschitzka F, Filippatos G, Volterrani M, Ponikowski P, Jankowska EA, Chioncel O, McDonagh TA, Piepoli MF, Milicic D, Thum T, Hill L, Abdelhamid M, Adamopoulos S, Belenkov Y, Gal TB, Böhm M, Cohen-Solal A, Gustafsson F, Jaarsma T, Moura B, Rakisheva A, Ristic A, Bayes-Genis A, Van Linthout S, Anker SD, Tocchetti CG, Lopatin Y, Lund L, **Savarese G**, Čelutkienė J, Cowie M, Lambrinou E, Ray R, Lainscak M, Skouri H, Wallner M, Rosano GMC
Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022. doi: 10.1002/ehjhf.2430. PMID: 35014132
7. Palazzuoli A, Savarese G
An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications.
Heart Fail Rev. 2022. doi: 10.1007/s10741-021-10202-w. PMID: 35067834
8. **Savarese G**, Stolfo D, Sinagra G, Lund LH.
Heart failure with mid-range or mildly reduced ejection fraction.
Nat Rev Cardiol. 2021. doi: 10.1038/s41569-021-00605-5. PMID: 34489589
<https://pubmed.ncbi.nlm.nih.gov/34489589/>
9. **Savarese G**, Lund LH, Rosano GMC, Coats AJ.
New trial evidence and guidelines on heart failure-news from the European Society of Cardiology Congress 2021
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab071. PMID: 34529057
<https://pubmed.ncbi.nlm.nih.gov/34529057/>
10. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, **Savarese G**, Pirmohamed M, Caulfield MJ.
Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Cardiovasc Pharmacother. 2021; doi: 10.1093/ehjcvp/pvab063. PMID: 34463331
<https://pubmed.ncbi.nlm.nih.gov/34463331/>
11. Becher PM, **Savarese G**.
PharmaPulse: New trial evidence from the HFA/ESC heart failure congress 2021
Eur Heart J Cardiovasc Pharmacother. 2021;pvab066. doi: 10.1093/ehjcvp/pvab066. PMID: 34415014
<https://pubmed.ncbi.nlm.nih.gov/34415014/>
12. **Savarese G**, Butler J, Lund LH, Bhatt DL, Anker SD.

Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms

Cardiovasc Res. 2021. doi: 10.1093/cvr/cvab271. PMID: 34390570

<https://pubmed.ncbi.nlm.nih.gov/34390570/>

13. Savarese G, Merlo M, Coats AJS, Metra M.

Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021

Eur J Heart Fail. 2021 Sep;23(9):1424-1427. PMID: 34263508

<https://pubmed.ncbi.nlm.nih.gov/34263508/>

14. Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, Dendale P, Seferovic P, Rosano G, Staplin N, Baigent C, Cosentino F.

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors

Eur J Heart Fail. 2021;23:1260-1275. PMID: 34184823

<https://pubmed.ncbi.nlm.nih.gov/34184823/>

15. Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S.

Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab048. PMID: 34180504

<https://pubmed.ncbi.nlm.nih.gov/34180504/>

16. Stolfo D, Savarese G.

Association between heart failure and cancer: is gender the answer?

Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ehhf.2261. PMID: 34114282

<https://pubmed.ncbi.nlm.nih.gov/34114282/>

17. Sinagra G, Pagura L, Stolfo D, Fabris E, Savarese G, Rapezzi C, Ferrari R, Merlo M.

Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice

Eur J Intern Med. 2021 Aug;90:10-15. PMID: 34090751

<https://pubmed.ncbi.nlm.nih.gov/34090751/>

18. Kapelios CJ, Canepa M, Savarese G, Lund LH.

Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle 'do no harm'?

Eur J Heart Fail. 2021;23:1068-1075. PMID: 33963796

<https://pubmed.ncbi.nlm.nih.gov/33963796/>

19. Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall

- S, Niessner A, **Savarese G**, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C.
Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab038.
PMID: 33956964
<https://pubmed.ncbi.nlm.nih.gov/33956964/>
20. Rao VN, Fudim M, **Savarese G**, Butler J.
Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem
Am J Med. 2021;134:1068-1070. PMID: 33939999
<https://pubmed.ncbi.nlm.nih.gov/33939999/>
21. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, **Savarese G**, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS.
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail. 2021;23:872-881. PMID: 33932268
22. Ferrannini G, **Savarese G**, Rydén L.
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Diabetes Res Clin Pract. 2021;175:108796. PMID: 33845051
<https://pubmed.ncbi.nlm.nih.gov/33845051/>
23. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, **Savarese G**, Pirmohamed M, Caulfield MJ.
The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab018.
PMID: 33638977
<https://pubmed.ncbi.nlm.nih.gov/33638977/>
24. Rosano G, Vitale C, **Savarese G**.
Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Eur Heart J Cardiovasc Pharmacother 2021. doi: 10.1093/ehjcvp/pvab012.
PMID: 33576409
<https://pubmed.ncbi.nlm.nih.gov/33576409/>
25. **Savarese G**.

New evidence from the scientific sessions 2020 of the American Heart Association

Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa143.
PMID: 33367726

<https://pubmed.ncbi.nlm.nih.gov/33367726/>

26. Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, **Savarese G**, Schmidt TA, Semb A, Tamargo J, Wassmann S, Kjeldsen KP, Agewall S, Pocock SJ.
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

Eur Heart J Cardiovasc Pharmacother. 2020. doi: 10.1093/ehjcvp/pvaa126.
PMID: 33135079

<https://pubmed.ncbi.nlm.nih.gov/33135079/>

27. Saraiva FA, Cerqueira RJ, **Savarese G**, Leite-Moreira AF.

The tight tie of MAG versus SAG in CABG

Int J Cardiol. 2020 Oct 7;S0167-5273(20)33919-X. doi:
10.1016/j.ijcard.2020.10.010. PMID: 33038409

<https://pubmed.ncbi.nlm.nih.gov/33038409/>

28. **Savarese G**.

Latest news on heart failure and atrial fibrillation from the European Society of Cardiology Congress 2020.

Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa115.
PMID: 33002119

<https://pubmed.ncbi.nlm.nih.gov/33002119/>

29. **Savarese G**, Cosentino F.

The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns

Eur Heart J. 2020 Sep 21;41(36):3419-3420. doi: 10.1093/eurheartj/ehaa584.
PMID: 32901257

<https://pubmed.ncbi.nlm.nih.gov/32901257/>

30. D'Amario D, Camilli M, Migliaro S, Canonico F, Galli M, Arcudi A, Montone RA, Borovac JA, Crea F, **Savarese G**.

Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology

Curr Cardiol Rep. 2020 Aug 8;22(10):102. doi: 10.1007/s11886-020-01377-z.
PMID: 32770480

<https://pubmed.ncbi.nlm.nih.gov/32770480/>

31. Kaski JC, Tamargo J, **Savarese G**.

Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):277-279. doi:
10.1093/ehjcvp/pvaa090. PMID: 32687147

<https://pubmed.ncbi.nlm.nih.gov/32687147/>

32. **Savarese G.**
All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):275-276. doi: 10.1093/ehjcvp/pvaa070.
<https://pubmed.ncbi.nlm.nih.gov/32584980/>
33. **Rosano G, Savarese G.**
Inter-twinned Relationship Between Heart Failure and Atrial Fibrillation
Heart 2020. doi: 10.1136/heartjnl-2020-316886. PMID: 32482671
<https://pubmed.ncbi.nlm.nih.gov/32482671>
34. **Stolfo D, Savarese G**
Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence
Eur J Heart Fail. 2020; doi: 10.1002/ehjhf.1761. PMID: 32103601
<https://www.ncbi.nlm.nih.gov/pubmed/32103601>
35. **Schrage B, Linde C, Braunshweig F, Savarese G**
Reply to the letter by Dr. Littmann
Circulation 2020;141:e648-e649. doi: 10.1161/CIRCULATIONAHA.120.045603. PMID: 32176544
<https://www.ncbi.nlm.nih.gov/pubmed/32176544>
36. **Savarese G.**
Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
Eur Cardiol 2019;14:139-140. PMID: 31933680
<https://www.ncbi.nlm.nih.gov/pubmed/31933680>
37. **Lund LH, Savarese G.**
PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction.
J Card Fail 2019;25:1012-1013. PMID: 31818392
<https://www.ncbi.nlm.nih.gov/pubmed/31818392>
38. **Lund LH, Savarese G, Dahlström U.**
Iron deficiency in heart failure.
Int J Cardiol 2020;299:207. PMID: 31791539
<https://www.ncbi.nlm.nih.gov/pubmed/31791539>
39. **Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.**
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
Eur Heart J 2019;40:3010-3012. PMID: 31541549
<https://www.ncbi.nlm.nih.gov/pubmed/31541549>

40. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, **Savarese G**, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother 2020;6:104-114. PMID: 31397840
<https://www.ncbi.nlm.nih.gov/pubmed/31397840>
41. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, **Savarese G**, Wassmann S, Agewall S.
The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials.
Eur Heart J Cardiovasc Pharmacother 2020;6:97-103. PMID: 31298686
<https://www.ncbi.nlm.nih.gov/pubmed/31298686>
42. Stolfo D, **Savarese G**.
Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction.
Card Fail Rev 2019;5:70-73. PMID: 31179014
<https://www.ncbi.nlm.nih.gov/pubmed/31179014>
43. **Savarese G**, Lund LH, Carrero JJ.
Reply: Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes.
JACC Heart Fail 2019;7:533-534. PMID: 31146879
<https://www.ncbi.nlm.nih.gov/pubmed/31146879>
44. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, **Savarese G**, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Eur Heart J Cardiovasc Pharmacother 2019;5:171-180. PMID: 31119266
<https://www.ncbi.nlm.nih.gov/pubmed/31119266>
45. Uijl A, Lund LH, **Savarese G**.
The GUIDE-IT heart failure risk prediction model: another fish in the sea?
Eur J Heart Fail 2019;21:779-780. PMID: 30983078
<https://www.ncbi.nlm.nih.gov/pubmed/30983078>
46. Galli M, Andreotti F, **Savarese G**, D'Amario D, Vergallo R, Della Bona R, Caló L, Porto I, Crea F
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
Eur Heart J Cardiovasc Pharmacother 2019;5:55-56. PMID: 30289484
<https://www.ncbi.nlm.nih.gov/pubmed/30289484>
47. **Savarese G**, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH.

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.

Ups J Med Sci 2019;124:65-69. PMID: 30092697

<https://www.ncbi.nlm.nih.gov/pubmed/30092697>

48. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, **Savarese G**, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J.

Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.

Eur Heart J Cardiovasc Pharmacother 2018;4:230-236. PMID: 30099530

<https://www.ncbi.nlm.nih.gov/pubmed/30099530>

49. Cooper LB, Savarese G, Carrero JJ, Szabo B, Jernberg T, Jonsson A, Dahlbom C, Dahlstrom U, Larson A, Lund LH.

Clinical and research implications of serum versus plasma potassium measurements.

Eur J Heart Fail 2019;21:536-537. PMID: 30485595

<https://www.ncbi.nlm.nih.gov/pubmed/30485595>

50. **Savarese G**, D'Amario D.

Sex Differences in Heart Failure.

Adv Exp Med Biol. 2018;1065:529-544. PMID: 30051405

<https://www.ncbi.nlm.nih.gov/pubmed/30051405>

51. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, **Savarese G**, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Eur Heart J Cardiovasc Pharmacother 2018;4:180-188. PMID: 29726985

<https://www.ncbi.nlm.nih.gov/pubmed/29726985>

52. Lund LH, Vedin O, **Savarese G**.

Is ejection fraction in heart failure a limitation or an opportunity?

Eur J Heart Fail. 2018;20:431-432. PMID: 29333631

<https://www.ncbi.nlm.nih.gov/pubmed/29333631>

53. Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, van Thiel GJ, Cronin M, Brobert G, Vardas P, Anker SD, Grobbee DE, Denaxas S; **BigData@Heart Consortium** .

Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.

Eur Heart J 2018;39:1481-1495. PMID: 29370377

<https://www.ncbi.nlm.nih.gov/pubmed/29370377>

54. **Savarese G**, Lund LH.

Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.

- Int J Cardiol 2017;249:77-78. PMID: 29121762
<https://www.ncbi.nlm.nih.gov/pubmed/29121762>
55. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, **Savarese G**, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J 2018;39:2274-2281. PMID: 29126266
<https://www.ncbi.nlm.nih.gov/pubmed/29126266>
56. **Savarese G**, Lund LH.
Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
Eur J Heart Fail 2018;20:370-372. PMID: 28980436
<https://www.ncbi.nlm.nih.gov/pubmed/28980436>
57. **Savarese G**, Lund LH.
Global Public Health Burden of Heart Failure.
Card Fail Rev 2017;3:7-11. PMID: 28785469
<https://www.ncbi.nlm.nih.gov/pubmed/28785469>
58. Prastaro M, Pirozzi E, Gaibazzi N, Paolillo S, Santoro C, **Savarese G**, Losi MA, Esposito G, Perrone Filardi P, Trimarco B, Galderisi M.
Expert Review on the Prognostic Role of Echocardiography after Acute Myocardial Infarction.
J Am Soc Echocardiogr 2017;30:431-443.e2. PMID: 28477781
<https://www.ncbi.nlm.nih.gov/pubmed/28477781>
59. Tamargo J, Rosano G, Thomas W, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, **Savarese G**, Torp-Pedersen C, Atar D, Lewis BS, Agewall S.
Gender differences in the effects of cardiovascular drugs.
Eur Heart J Cardiovasc Pharmacother 2017;3:163-182. PMID: 28329228
<https://www.ncbi.nlm.nih.gov/pubmed/28329228>
60. **Savarese G**, Lund LH.
Digoxin: Beneficial or Harmful?
Eur Heart J Cardiovasc Pharmacother 2017;3:127-128. PMID: 28206589
<https://www.ncbi.nlm.nih.gov/pubmed/28206589>
61. **Savarese G**, Lund LH, Rosano GM.
Incretin-based therapy for type 2 diabetes: A real class effect?
Int J Cardiol 2016;227:141-142. PMID: 27866064
<https://www.ncbi.nlm.nih.gov/pubmed/27866064>
62. **Savarese G**, Perrone-Filardi P.
Reply to: Ezetimibe: A real effect?
Int J Cardiol 2016;209:337-8. PMID: 26874996
<https://www.ncbi.nlm.nih.gov/pubmed/26874996>

63. Camici GG, **Savarese G**, Akhmedov A, Lüscher TF.
Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.
Eur Heart J 2015;36:3392-403. PMID: 26543043
<https://www.ncbi.nlm.nih.gov/pubmed/26543043>
64. Perrone-Filardi P, Paolillo S, Costanzo P, **Savarese G**, Trimarco B, Bonow RO.
The role of metabolic syndrome in heart failure.
Eur Heart J 2015;36:2630-4. PMID: 26242711
<https://www.ncbi.nlm.nih.gov/pubmed/26242711>
65. **Savarese G.**
Vitamin D and parathyroid hormone: a new piece in the puzzle of cardiovascular risk.
J Cardiovasc Med (Hagerstown) 2015;16:71. PMID: 25427049
<https://www.ncbi.nlm.nih.gov/pubmed/25427049>
66. Prastaro M, D'Amore C, Paolillo S, Losi M, Marciano C, Perrino C, Ruggiero D, Gargiulo P, **Savarese G**, Trimarco B, Perrone Filardi P.
Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction.
Heart Fail Rev 2015;20:305-16. PMID: 25355298
<https://www.ncbi.nlm.nih.gov/pubmed/25355298>
67. Gargiulo P, Cuocolo A, Dellegrottaglie S, Prastaro M, **Savarese G**, Assante R, Zampella E, Paolillo S, Scala O, Ruggiero D, Marsico F, Perrone Filardi P.
Nuclear Assessment of Right Ventricle.
Echocardiography 2015;32 Suppl 1:S69-74. PMID: 25238036
<https://www.ncbi.nlm.nih.gov/pubmed/25238036>
68. **Savarese G**, Perrone-Filardi P.
Reply to Letter to the Editor: "Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease"
J Am Coll Cardiol 2014;63:2303. PMID: 24727257
<https://www.ncbi.nlm.nih.gov/pubmed/24727257>
69. Dellegrottaglie S, Guarini P, **Savarese G**, Gambardella F, Iudice FL, Cirillo A, Vitagliano A, Formisano T, Pellegrino AM, Bossone E, Perrone-Filardi P.
Cardiac magnetic resonance for the assessment of myocardial viability: from pathophysiology to clinical practice.
J Cardiovasc Med (Hagerstown) 2013;14:862-9. PMID: 23756415
<https://www.ncbi.nlm.nih.gov/pubmed/23756415>
70. Bossone E, **Savarese G**, Ferrara F, Citro R, Mosca S, Musella F, Limongelli G, Manfredini R, Cittadini A, Perrone-Filardi P
Takotsubo cardiomyopathy: overview
Heart Fail Clin 2013;9:249-66. PMID: 23562126
<https://www.ncbi.nlm.nih.gov/pubmed/23562126>

71. Perrone-Filardi P, Musella F, **Savarese G**, Cecere M, Marciano C, Scala O, MD1, Rengo G, Dellegrottaglie S, Cuocolo A, Leosco D.
Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification.
Eur Heart J Cardiovasc Imaging 2012;13:453-8. PMID: 22523008
<https://www.ncbi.nlm.nih.gov/pubmed/22523008>
72. Perrone-Filardi P, **Savarese G**, Rengo G, Mattiello G, Leosco D.
Viability and left ventricular dysfunction: what changes after STICH?
G Ital Cardiol 2012;13:81-3. PMID: 22322546
<https://www.ncbi.nlm.nih.gov/pubmed/22322546>
73. **Savarese G**, Losco T, Parente A, Musella F, Pirozzi E, Mosca S, Casaretti L, Formisano R, Conte S, Bologna A, Mattiello G, Perrone-Filardi P.
Clinical applications of MIBG SPECT in chronic heart failure
G Ital Cardiol 2012;13:91-7. PMID: 22322548
<https://www.ncbi.nlm.nih.gov/pubmed/22322548>
74. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, **Savarese G**, Marciano C, Casaretti L, Cecere M, Musella F, Pirozzi E, Parente A, Cuocolo A.
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal.
Heart 2011;97:1828-33. PMID: 21917663
<https://www.ncbi.nlm.nih.gov/pubmed/21917663>
75. Perrone-Filardi P, Costanzo P, Dellegrottaglie S, Gargiulo P, Ruggiero D, **Savarese G**, Parente A, D'Amore C, Cuocolo A, Chiariello M.
Prognostic role of myocardial single photon emission computed tomography in the elderly
Journal of Nuclear Cardiology 2010;17:310-5. PMID: 20033857
<https://www.ncbi.nlm.nih.gov/pubmed/20033857>
76. Monda C, Scala O, Paolillo S, **Savarese G**, Cecere M, D'Amore C, Parente A, Musella F, Mosca S, Filardi PP.
Sleep apnea and heart failure: pathophysiology, diagnosis and therapy.
G Ital Cardiol 2010;11:815-22. PMID: 21348318
<https://www.ncbi.nlm.nih.gov/pubmed/21348318>
77. Filardi PP, Cecere M, **Savarese G**, Damore C, Parente A, Conte S, Coutsoumbas G.
Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?
G Ital Cardiol 2010;11(12 Suppl 3):10S-15S. PMID: 21491734
<https://www.ncbi.nlm.nih.gov/pubmed/21491734>

3 INTERNATIONAL SCIENTIFIC CONGRESSES

3.1 Invited speaker or chair

1. Antiarrhythmics (chairman)

Pharmacotherapy in Older People – European Society of Cardiology, Working group on Cardiovascular Pharmacotherapy. London, 25 October 2019

2. **A case of a patient with chronic kidney disease and hyperkalemia: how to optimise RAAS inhibitors? (speaker)**
Heart Failure 2019 and World congress on acute heart failure (HFA). Athens, 25-28 May 2019.
3. **Management of peripheral arterial disease (speaker)**
The Year in Cardiology. Dubai, 22-24 February 2019
4. **Update on the ESC guidelines on arterial hypertension (speaker)**
The Year in Cardiology. Dubai, 22-24 February 2019
5. **RAS and natriuretic peptides role in heart failure (speaker)**
“Napoli Cuore” Congress. Naples, 23 March 2018
6. **Unmet needs in heart failure in 2018 (speaker)**
Cardiovascular Pharmacotherapy: from the population to the individual. Moscow, 21 April 2018
7. **Heart Failure (chairman)**
Cardiovascular Pharmacotherapy: from the population to the individual. Moscow, 21 April 2018
8. **Heart failure with recovered EF (speaker)**
Heart failure 2030: cutting the edge of the failing heart
Pisa, 23-24 April 2018
9. **Cardiovascular pharmacologists and trialists of tomorrow (chairman)**
EuroCVP 2018 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Tel Aviv, 13-14 May 2018
10. **Potential of real-world data analysis (speaker)**
proCardio2018. Madrid, 29-30 October 2018
11. **Interpreting Meta-Analyses and Clinical Trials: Can we Believe the Data? (speaker)**
ICCAD 2017 – Innovations in coronary artery disease. Venice, 15-17 October 2017
12. **Clinical trial design and statistical methods (speaker)**
ESC Congress 2017. Barcelona, 26-30 August 2017
13. **Cardiovascular risk in diabetics (speaker)**
EuroCVP 2017 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017
14. **Cardiovascular pharmacologists and trialists of tomorrow (chairman)**
EuroCVP 2017 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017

3.2 Oral presentations of own accepted abstracts

1. **How many real world HFpEF patients would be suitable for sacubitril/valsartan treatment according to the PARAGON-HF trial**
Late breaking trial session. Heart failure 2020 and World congress on acute heart failure (HFA) held online as HFA Discoveries in June 2020
2. **Association between beta-blocker use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective score-matched cohort study**
Late breaking trial session. European Society of Cardiology Congress 2019. Paris, 31 August – 4 September 2019
3. **Empagliflozin is associated with a lower risk of post-acute heart failure re-hospitalization and mortality: insights from the EMPA-REG Outcome trial**
Highlight session on Heart Failure. American College of Cardiology.19, 68th Annual Scientific Session and Expo. New Orleans, 16-18 March 2019
4. **Optimizing patient selection in heart failure trials: the role of NT-proBNP**
European Society of Cardiology Congress 2018. Munich, 31 August – 4 February 2018
5. **Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort**
Late breaking trial session. Heart failure 2018 and World congress on acute heart failure (HFA). Vienna, 26-29 May 2018
6. **Incidence of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction: an analysis of 6,401 patients from the swedish heart failure registry**
Young investigator award session. Heart failure 2018 and World congress on acute heart failure (HFA). Vienna, 26-29 May 2018
7. **Savarese G, Lund LH, Dahlstrom U, Stromberg A.**
Predictors of and outcomes associated with referral to a heart failure nurse-led clinic: an analysis of 40,992 patients from the Swedish Heart Failure Registry
American College of Cardiology.18, 67th Annual Scientific Session and Expo. Orlando, 10-12 March 2018.
8. **Impact of CHA2DS2-VASc and HAS-BLED SCORES on oral anticoagulant use and outcomes in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,055 patients from the SwedeHF (finalist Young Investigator Award on Population Science)**
European Society of Cardiology Congress 2017. Barcelona, 26-30 August 2017
9. **Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction**

European Society of Cardiology Congress 2017. Barcelona, 26-30 August 2017

10. **Use of mineralocorticoid receptor antagonists in a real-world population with heart failure and reduced ejection fraction: an analysis of 24,529 patients from the Swedish heart failure registry**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017
11. **Oral anticoagulant use in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,719 patients from the Swedish heart failure registry**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017
12. **Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry**
Highlight session on Heart Failure. American College of Cardiology.17, 66th Annual Scientific Session and Expo. Washington, 17-19 March 2017.
13. **Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registry**
European Society of Cardiology Congress 2016. Rome, 27-31 August 2016.
14. **Efficacy and safety of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis**
European Society of Cardiology Congress 2016. Rome, 27-31 August 2016.
15. **Efficacy and safety of dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of 116 trials.**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Florence, 21-24 May 2016.
16. **Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction**
European Society of Cardiology Congress 2015, London, 29 August – 2 September 2015
17. **Novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis**
European Society of Cardiology Congress 2015, London, 29 August – 2 September 2015
18. **Efficacy and Safety of Novel Oral Anticoagulants in Patients with Atrial Fibrillation and Heart Failure: A Meta-Analysis of Phase III Clinical Trials.**
American College of Cardiology.15, 64th Annual Scientific Session and Expo. San Diego, 14-16 March 2015.

19. **Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients: A Meta-Analysis of 95 Trials.**
American Heart Association Scientific Session 2014. Chicago, 15-19 Nov 2014
20. **Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial**
European Society of Cardiology Congress 2014. Barcelona, 29 Aug – 2 Sep 2014
21. **Prognostic Impact of Metabolic Syndrome in Patients With Chronic Heart Failure: Data From Gissi-Hf Trial**
American Heart Association Scientific Session 2013. Dallas, 16 - 20 November 2013.
22. **Benefits of statins in elderly subjects without established cardiovascular disease. a meta-analysis.**
European Society of Cardiology Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
23. **Changes of urinary albumin excretion and cardiovascular events: a meta-regression analysis of 32 randomized trials and 80,812 patients.**
European Society of Cardiology Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
24. **Do Changes of Urinary Albumin Excretion Predict Cardiovascular Events? A Meta-regression Analysis of 32 Randomized Trials.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
25. **Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality and Cardiovascular Events in Patients Without Heart Failure. A Meta-Analysis of Randomized Clinical Trials in 108,233 patients.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
26. **Left Ventricular Hypertrophy Reduction and Clinical Events. A Meta-regression Analysis of 14 Studies in 12,809 Hypertensive Patients.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
27. **Effects of atorvastatin and rosuvastatin on renal function in patients at high cardiovascular risk: a meta-analysis of 21 randomized trials.**
European Society of Cardiology Congress 2012. Munich, 25-29 August 2012.

3 EVALUATION OF OTHERS' WORK

3.1. Serving as reviewer for international evaluations

- Reviewer for case reports submitted to the Heart Failure and the World Congress on Acute Heart Failure (Heart Failure Association – European Society of Cardiology) 2016 and 2017
- Member of the European Society of Cardiology (ESC) Abstract Reviewing Committee – 2018 and 2019
- Reviewers for abstracts submitted to the Heart Failure and the World Congress on Acute Heart Failure (Heart Failure Association – European Society of Cardiology) 2019, 2020 and 2021
- Member of the European Society of Cardiology (ESC) Abstract Reviewing Committee - 2020
- Reviewer for the Abstracts submitted to the American College of Cardiology Congress 2020

3.2 Evaluator of major research applications in national competition

- Reviewer for the French National Research Agency (ANR) 2021
- Reviewer for the British Heart Foundation in 2019-2020
- Reviewer for the Deutsche Forschungsgemeinschaft (DFG) in 2020 and 2021
- Reviewer for Italian Board of education, university and research- funded projects in 2019-2020
- Netherlands Organisation for Scientific Research – Innovational research grants (VIDI) in 2019
- Reviewer for research grants in the United Arab Emirates in 2018

3.3 Editor of scientific journals

- Associate Editor of Plos One (2018 – ongoing)
- Deputy Editor of European Heart Journal - Case Reports (2020 – ongoing; previously Associate Editor since 2017)
- Section Editor for Heart Failure of European Heart Journal – Open (2021 – ongoing)

3.4 Member of an editorial board

- Plos One (2018 – ongoing)
- Cardiology and Therapy (2017 – ongoing)
- European Cardiology Review (2019 – ongoing)
- European Heart Journal – Cardiovascular Pharmacotherapy (2020 – ongoing)

3.5 Referee for scientific journals

Around 70 Reviews per year from the following journals:

- Journal of American College of Cardiology

- European Heart Journal
- Circulation
- European Journal of Heart Failure
- Circulation: Heart failure
- Annals of Internal Medicine
- International Journal of Cardiology
- Cardiovascular Research
- Journal of Cardiovascular Medicine
- Journal of Cardiac Failure
- European Heart Journal - Cardiovascular Pharmacotherapy
- American Journal of Cardiology
- European Heart Journal – Case Reports
- European Cardiology Review
- Nutrition, Metabolism and Cardiovascular diseases
- European Journal of Cardiovascular Nursing
- Cardiology and Therapy
- ESC Heart Failure
- Scandinavian Cardiovascular Journal
- Cardiac Failure Review
- Journal of Hypertension

3.6 Reviewer or advisor for other scientific bodies


- EMA (European Medicines Agency) – AIFA (Italian Drug Agency) (2012)
- Clinical Event Adjudication (CEA) for randomized trials – Uppsala Clinical Research Center, Uppsala, Sweden (2016 – ongoing) for the trials DAPA-HF, DAPA-CKD, DAPA-MI, FULL REVASC (GCP training in October 2021)

KEY TEACHING ACTIVITIES

- >400 certified hours of teaching
- Director of the PhD Course “Clinical Trials in Cardiovascular Research” at KI, in collaboration with the European Society of Cardiology – WG on cardiovascular pharmacotherapy
- Director of the PhD Course “Clinical Trials in Heart Failure” at KI, in collaboration with the Heart Failure Association of the European Society of Cardiology
- Board, Committee for the Education of the Heart Failure Association of the European Society of Cardiology
- Faculty, MSc in clinical trials at the Oxford University

- Faculty, MSc in Heart Failure at St. George University, London, UK
- Faculty, PhD program, Sant'Anna School of Advanced Studies, Pisa, Italy
- Currently main supervisor of 5 PhD students at KI
- Currently co-supervisor of 3 PhD students at KI
- Currently supervisor of 1 Post Doc at KI
- Main Supervisor of 5 students for the MD degree project (2019-2021)

Stockholm, December 5th 2022

A handwritten signature in cursive script, reading "Gianluigi Savarese", written in black ink. The signature is fluid and stylized, with a horizontal line underneath it.